astragaloside a has been researched along with Pulmonary Arterial Hypertension in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y; Lu, ML; Tang, BL; Wang, HX | 1 |
| Li, R; Liu, D; Ma, Y; Xi, J | 1 |
2 other study(ies) available for astragaloside a and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Astragaloside IV improves pulmonary arterial hypertension by increasing the expression of CCN1 and activating the ERK1/2 pathway.
Topics: Animals; Disease Models, Animal; Endothelial Cells; Epidermal Growth Factor; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Hypoxia; Male; MAP Kinase Signaling System; Oxygen; Pulmonary Arterial Hypertension; Pulmonary Artery; Rats; Rats, Sprague-Dawley | 2023 |
Astragaloside IV restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway.
Topics: Animals; Cell Proliferation; Fibrosis; Hypertension, Pulmonary; Hypoxia; Myocytes, Smooth Muscle; Prolyl Hydroxylases; Pulmonary Arterial Hypertension; Pulmonary Artery; Pyroptosis; Rats; Signal Transduction | 2023 |